Abstract

One of the key challenges in cancer research is how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the main reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.

Keywords

Cancer researchCancer cellCancerBiologyGenetics

MeSH Terms

AnimalsAntineoplastic AgentsDrug ResistanceNeoplasmFerroptosisHumansIronLipid PeroxidationMolecular Targeted TherapyNeoplasmsSignal Transduction

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
review
Volume
35
Issue
6
Pages
830-849
Citations
2403
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2403
OpenAlex
55
Influential
1991
CrossRef

Cite This

Behrouz Hassannia, Peter Vandenabeele, Tom Vanden Berghe (2019). Targeting Ferroptosis to Iron Out Cancer. Cancer Cell , 35 (6) , 830-849. https://doi.org/10.1016/j.ccell.2019.04.002

Identifiers

DOI
10.1016/j.ccell.2019.04.002
PMID
31105042

Data Quality

Data completeness: 90%